Fuller & Thaler Asset Management, Inc. Rigel Pharmaceuticals Inc Transaction History

Fuller & Thaler Asset Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$1.6 - $2.43 $1.16 Million - $1.76 Million	-723,868 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$2.02 - $2.61 $7,676 - $9,918	-3,800 Reduced 0.52%	723,868 $1.89 Million
Q1 2019 May 14, 2019	BUY	$2.0 - $2.65 $44,320 - $58,724	22,160 Added 3.14%	727,668 $1.87 Million
Q4 2018 Feb 14, 2019	SELL	$2.08 - $3.36 $1,331 - $2,150	-640 Reduced 0.09%	705,508 $1.62 Million
Q3 2018 Nov 13, 2018	BUY	$2.6 - $3.59 $1.84 Million - $2.54 Million	706,148 New	706,148 $2.27 Million

335K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $3.72B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Fuller & Thaler Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Fuller & Thaler Asset Management, Inc. with notifications on news.